Literature DB >> 29018988

Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Angelo Corti1,2, Fabrizio Marcucci3, Tiziana Bachetti4.   

Abstract

Chromogranin A (CgA), a secretory protein released in the blood by neuroendocrine cells and neurons, is the precursor of various bioactive fragments involved in the regulation of the cardiovascular system, metabolism, innate immunity, angiogenesis, and tissue repair. After the original demonstration that circulating CgA can serve as a biomarker for a wide range of neuroendocrine tumors, several studies have shown that increased levels of CgA can be present also in the blood of patients with cardiovascular, gastrointestinal, and inflammatory diseases with, in certain cases, important diagnostic and prognostic implications. Considering the high structural and functional heterogeneity of the CgA system, comprising precursor and fragments, it is not surprising that the different immunoassays used in these studies led, in some cases, to discrepant results. Here, we review these notions and we discuss the importance of measuring total-CgA, full-length CgA, specific fragments, and their relative levels for a more thorough assessment of the pathophysiological function and diagnostic/prognostic value of the CgA system.

Entities:  

Keywords:  Cardiovascular diseases; Catestatin; Chromogranin A; Inflammatory diseases; Neuroendocrine tumors; Serpinin; Vasostatins

Mesh:

Substances:

Year:  2017        PMID: 29018988     DOI: 10.1007/s00424-017-2030-y

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  107 in total

1.  The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells.

Authors:  Anna Blois; Boleslaw Srebro; Maurizio Mandalà; Angelo Corti; Karen B Helle; Guldborg Serck-Hanssen
Journal:  Regul Pept       Date:  2006-05-24

2.  High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment.

Authors:  G Di Comite; P Previtali; C M Rossi; G Dell'Antonio; P Rovere-Querini; L Praderio; L Dagna; A Corti; C Doglioni; A Maseri; M G Sabbadini; A A Manfredi
Journal:  Ann Rheum Dis       Date:  2009-02       Impact factor: 19.103

3.  Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology.

Authors:  A Iyoda; K Hiroshima; T Toyozaki; Y Haga; T Fujisawa; H Ohwada
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

Review 4.  Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.

Authors:  A Berruti; L Dogliotti; A Mosca; G Gorzegno; E Bollito; M Mari; R Tarabuzzi; M Poggio; M Torta; D Fontana; A Angeli
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

5.  Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction.

Authors:  Mette Elise Estensen; Aina Hognestad; Unni Syversen; Iain Squire; Leong Ng; John Kjekshus; Kenneth Dickstein; Torbjørn Omland
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

6.  Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Silvia Capellino; Torsten Lowin; Peter Angele; Werner Falk; Joachim Grifka; Rainer H Straub
Journal:  J Rheumatol       Date:  2007-12-01       Impact factor: 4.666

7.  A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.

Authors:  Mats Stridsberg; Barbro Eriksson; Kjell Oberg; Eva Tiensuu Janson
Journal:  Regul Pept       Date:  2004-03-15

8.  Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion.

Authors:  Tiffany A Greenwood; Fangwen Rao; Mats Stridsberg; Nitish R Mahapatra; Manjula Mahata; Elizabeth O Lillie; Sushil K Mahata; Laurent Taupenot; Nicholas J Schork; Daniel T O'Connor
Journal:  Physiol Genomics       Date:  2006-03-22       Impact factor: 3.107

9.  Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart.

Authors:  Claudia Penna; Giuseppe Alloatti; Maria Pia Gallo; Maria Carmela Cerra; Renzo Levi; Francesca Tullio; Eleonora Bassino; Serena Dolgetta; Sushil K Mahata; Bruno Tota; Pasquale Pagliaro
Journal:  Cell Mol Neurobiol       Date:  2010-11-23       Impact factor: 5.046

10.  Prognostic value of circulating chromogranin A levels in acute coronary syndromes.

Authors:  Anna M Jansson; Helge Røsjø; Torbjørn Omland; Thomas Karlsson; Marianne Hartford; Allan Flyvbjerg; Kenneth Caidahl
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

View more
  12 in total

1.  Catestatin selects for colonization of antimicrobial-resistant gut bacterial communities.

Authors:  Pamela González-Dávila; Markus Schwalbe; Arpit Danewalia; Boushra Dalile; Kristin Verbeke; Sushil K Mahata; Sahar El Aidy
Journal:  ISME J       Date:  2022-04-19       Impact factor: 11.217

Review 2.  Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.

Authors:  Ali Pirasteh; Petra Lovrec; Lisa Bodei
Journal:  Rev Endocr Metab Disord       Date:  2021-03-30       Impact factor: 9.306

3.  Chromogranin A plasma levels predict mortality in COVID-19.

Authors:  Rebecca De Lorenzo; Clara Sciorati; Giuseppe A Ramirez; Barbara Colombo; Nicola I Lorè; Annalisa Capobianco; Cristina Tresoldi; Daniela M Cirillo; Fabio Ciceri; Angelo Corti; Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.240

4.  Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.

Authors:  Andrea Corsello; Luigi Di Filippo; Sara Massironi; Federica Sileo; Anna Dolcetta Capuzzo; Marco Gemma; Claudia Carlucci; Claudio Cusini; Barbara Colombo; Alice Dallatomasina; Giulia Maria Franchi; Angelo Corti; Marco Federico Manzoni
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

Review 5.  Catestatin as a Target for Treatment of Inflammatory Diseases.

Authors:  Elke M Muntjewerff; Gina Dunkel; Mara J T Nicolasen; Sushil K Mahata; Geert van den Bogaart
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

Review 6.  Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

Review 7.  The goldfish Carassius auratus: an emerging animal model for comparative cardiac research.

Authors:  Mariacristina Filice; Maria Carmela Cerra; Sandra Imbrogno
Journal:  J Comp Physiol B       Date:  2021-08-28       Impact factor: 2.200

8.  Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.

Authors:  Małgorzata Fuksiewicz; Maria Kowalska; Agnieszka Kolasińska-Ćwikła; Jarosław B Ćwikła; Łukasz Sawicki; Katarzyna Roszkowska-Purska; Joanna Drygiel; Beata Kotowicz
Journal:  Endocr Connect       Date:  2018-05-03       Impact factor: 3.335

Review 9.  Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.

Authors:  Sushil K Mahata; Angelo Corti
Journal:  Ann N Y Acad Sci       Date:  2019-10-06       Impact factor: 5.691

10.  Serum chromogranin A correlated with albuminuria in diabetic patients and is associated with early diabetic nephropathy.

Authors:  Hui Yu; Hongping Wang; Xue Su; Aili Cao; Xingmei Yao; Yunman Wang; Bingbing Zhu; Hao Wang; Ji Fang
Journal:  BMC Nephrol       Date:  2022-01-21       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.